514 - The Impact of Xeruborbactam on in vitro Activity of Cefiderocol against a Panel of Acinetobacter baumannii Enriched in Isolates with Reduced Cefiderocol Susceptibility

Co-Author(s)

• TH

  Takafumi Hara, MSc (he/him/his)

  Researcher
  Shionogi & Co., Ltd.
  Toyonaka, Osaka, Japan

  Slides

Co-Author(s)

• NI

  Naoki Ishibashi, MD

  Pharmaceutical Research Division
  Osaka, Osaka, Japan
• DM

  Dai Miyagawa, n/a

  Shionogi & Co., Ltd.
  Toyonaka, Osaka, Japan
• MO

  Motoyasu Onishi, PhD

  Manager
  Shionogi & Co., Ltd.
  Toyonaka, Osaka, Japan
• OL

  Olga Lomovskaya, PhD

  Qpex Biopharma Inc.
  San Diego, California, United States

Presenting Author(s)

• 

  Yoshinori Yamano, PhD (he/him/his)

  Chief Scientific Officer for Infectious Diseases
  Shionogi & Co., Ltd.
  Toyonaka, Osaka, Japan

  Slides